top of page

Adamas submits new drug application to FDA for ADS-5102

Adamas Pharmaceuticals has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for ADS-5102 (amantadine hydrochloride) extended-release capsules, the company's lead product candidate, for the potential treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page